Evidence map›Paper›PMID 20835396›Full record

ArticleJournal of ocular biology, diseases, and informatics2009

Ocular disease in patients with ANCA-positive vasculitis.

Angela S Watkins, John H Kempen, Dongseok Choi, Teresa L Liesegang, S S Pujari, Craig Newcomb, Robert B Nussenblatt, James T Rosenbaum, Jennifer E Thorne, C Stephen Foster and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of ocular biology, diseases, and informatics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Choroidal involvement in systemic vasculitis: a systematic review.Journal of ophthalmic inflammation and infection · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Angela S Watkins
John H Kempen
Dongseok Choi
Teresa L Liesegang
S S Pujari
Craig Newcomb
Robert B Nussenblatt
James T Rosenbaum
Jennifer E Thorne
C Stephen Foster
Douglas A Jabs
Grace A Levy-Clarke
Eric B Suhler
Justine R Smith
Oregon Health & Science University · USMassachusetts Eye Research and Surgery Institute · USJohns Hopkins Medicine · USJohns Hopkins University · USNational Eye Institute · USPenn Presbyterian Medical Center · USSt. Luke's Cataract and Laser Institute · USUniversity of Pennsylvania · US

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Complications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159k
NEI NIH HHS R01 EY014943NEI NIH HHS R56 EY014943
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis-the term recently applied to Wegener's granulomatosis-is a rare multi-system inflammation characterized by necrotizing granulomas and vasculitis. We investigated the ocular manifestations of this disease in a group of patients drawn from five inflammatory eye disease clinics across the United States. Of 8,562 persons with ocular inflammation, 59 individuals were diagnosed with ANCA-positive vasculitis; 35 males and 21 females, aged 16 to 96 years, were included in this study. Ocular diagnoses were scleritis (75.0%), uveitis (17.9%), and other ocular inflammatory conditions (33.9%) including peripheral ulcerative keratitis and orbital pseudotumor. Mean duration of ocular disease was 4.6 years. Oral corticosteroids and other systemic immunosuppressive agents were used by 85.7% and 78.5% of patients, respectively. Over time, patients with ANCA-positive vasculitis experienced 2.75-fold higher mortality than other patients with inflammatory eye disease.

Identifiers

PMID20835396
PMCPMC2933008
OpenAlexW2026923232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.